People at high risk for recurrent cardiac events following percutaneous coronary intervention (PCI), a procedure to open ...

Late-breaking data showed almost all patients achieved normal blood clotting and vessel repair after bentracimab infusion.

Patients who have a stent implanted to open a blocked coronary artery face dual risks of developing blood clots and of having ...

The cyclooxygenase-2 inhibitors are not antiplatelet drugs. [2] In 1998 only one drug in this class was available, a monoclonal antibody (abciximab) directed against the fibrinogen receptor on the ...

A is a graph comparing the occurrence of ischemic stroke and major bleeding (cerebral hemorrhage, intestinal hemorrhage ...

Two common medications that are categorized as blood thinners and used to prevent blood clots are anticoagulants and ...

Three months of dual antiplatelet therapy after PCI may safely balance thrombosis and bleeding risk in both patients with low ...

A study from the Karolinska Institutet in Sweden has found that some commonly used cardiovascular medications are linked to a ...

A drug developed as an antidote to the antiplatelet agent ticagrelor safely and effectively reversed ticagrelor’s antiplatelet effects in patients ...

No writing assistance was utilized in the production of this manuscript. The combined use of antiplatelet drugs acting through different mechanisms is important in antithrombotic treatment of ...

Christian T. Ruff, MD, MPH, of Brigham and Women's Faulkner Hospital, discusses new data comparing abelacimab with ...